Please upgrade your browser.
Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium
“We are excited to present interim data from the ongoing Phase IIa clinical trial showing that Archexin, in combination with everolimus (Afinitor®), appears to be safe and well tolerated at the doses tested to date.
The clinical development program for avelumab now includes more than 1,400 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal (GEJ) cancers, head and neck cancer, Merkel cell carcinoma, melanoma, NSCLC, ovarian cancer, renal cell carcinoma and urothelial (e.g., bladder) cancer.
We aimed to investigate whether expression in the primary tumour of genes involved in the development of BM is associated with outcome in m-ccRCC patients treated with anti-VEGFR-TKIs.
Tumor-specific alternative splicing is implicated in the progression of cancer, including clear-cell renal cell carcinoma (ccRCC).
Clear cell renal cell carcinomas (ccRCCs) display divergent clinical behaviours. Molecular markers might improve risk stratification of ccRCC.
Post-hoc analysis suggested that nintedanib may have been particularly effective in patients with liver metastases at baseline, extending both PFS (8.4 vs 5.6 months) and OS (12.1 vs 8.2 months) compared with sunitinib.
Lenvatinib Phase II Results Show Significant Improvement in Progression-Free Survival When Used With Everolimus
Phase II results show lenvatinib, when used in combination with everolimus, demonstrates significantly improved progression-free survival (PFS) versus everolimus alone in people with metastatic renal cell carcinoma (mRCC) following prior VEGF-targeted therapy.
This is a Phase II study to evaluate the efficacy and safety of savolitinib monotherapy (600 mg once daily) in papillary renal cell carcinoma (“PRCC”) in the United States, Canada and Europe. PRCC represents about 14% of all new cases of kidney cancer.
A gender discrepancy exists in the incidence of both urothelial and kidney carcinomas, with more men presenting with these cancers than women. Men have a threefold greater risk of developing bladder cancer than women, but female gender has been identified as an independent adverse prognostic factor for both recurrence and progression of this disease.
Researchers have found that real-world metastatic renal cell cancer patients being treated with tyrosine kinase inhibitors are often sicker than subjects in clinical trials for these drugs, leading to questions about safety for use in the very patients who need the drugs in clinical practice.
|Powered by NeonCRM|